The total return over the past 12 months is +28.96% vs. +16.94% for the S&P 500. So far it's up +20.59% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +28.96% | (1.98%) | (16.91%) | N/A | N/A | N/A |
| Total Return CAGR | +28.96% | (1.98%) | (16.91%) | N/A | N/A | N/A |
| Revenue CAGR | N/A | (78.09%) | +20.68% | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Denali Therapeutics Inc. (DNLI)
| Year | Start price | End price | DNLI Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $16.51 | $19.91 | +20.59% | +14.51% | +6.08% |
| 2025 | $20.38 | $16.51 | (18.99%) | +17.72% | (36.71%) |
| 2024 | $21.46 | $20.38 | (5.03%) | +24.89% | (29.92%) |
| 2023 | $27.81 | $21.46 | (22.83%) | +26.19% | (49.02%) |
| 2022 | $44.60 | $27.81 | (37.65%) | (18.17%) | (19.48%) |
| 2021 | $83.76 | $44.60 | (46.75%) | +28.74% | (75.49%) |
| 2020 | $17.42 | $83.76 | +380.83% | +18.37% | +362.46% |
| 2019 | $20.66 | $17.42 | (15.68%) | +31.22% | (46.90%) |
| 2018 | $15.64 | $20.66 | +32.10% | (4.56%) | +36.66% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
